81.1%
solid or hematologic malignanciesadvanced or metastatic canceradvanced/metastatic cancerGustave RoussyREISAMICanti-PD-(L)1anti-programmed death-ligand 1 (PD-(L)1)
…etween December 2014 and December 2023, we included adults with solid or hematologic malignancies who presented with irAEs after the first infusion of anti-PD-(L…